Revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aytu Biopharma, Inc (AYTU)
Price$2.05Cached quote
Net income
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M | $3.7M | $3.2M | $2.6M | $261,782 | $58,929 | $1,750 | $1,750 | — | — | — | — | — | — |
| Gross profit | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | $5.1M | $1.6M | $1.8M | $1.6M | $173,673 | — | — | — | — | — | — | — | — | — |
| Gross margin | 69.04% | 75.26% | 62.04% | 54.08% | 44.49% | 70.03% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | — | — | — | — | — | — | — | — | — |
| Research & development | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589,072 | $167,595 | $959,857 | $6.1M | $3.2M | $3.9M | — | — | — | — | — | — | — | — |
| Operating expenses | $53.7M | $50.6M | $83.7M | $162.2M | $88.1M | $40.5M | $24.2M | $23.4M | $23.3M | $24.3M | $7.9M | — | — | — | — | — | — | — | — | — |
| Operating income | −$7.8M | −$1.6M | −$17.1M | −$109.9M | −$58.9M | −$21.1M | −$16.8M | −$19.7M | −$20.1M | −$21.7M | −$7.6M | −$6.3M | −$52,414 | −$56,356 | −$133,619 | — | — | — | — | — |
| Operating margin | −11.79% | −2.44% | −15.89% | −113.69% | −89.70% | −76.47% | −230.15% | −538.26% | −624.70% | −847.02% | −2,915.53% | −10,770.31% | −2,995.09% | −3,220.34% | — | — | — | — | — | — |
| EBITDA | −$2.5M | $6.7M | −$8.3M | −$99.8M | −$49.7M | −$15.4M | −$14.1M | −$17.1M | −$15.8M | −$20.8M | −$7.5M | −$6.2M | $5,937 | −$2,947 | −$126,856 | — | — | — | — | — |
| EBITDA margin | −3.69% | 10.25% | −7.68% | −103.20% | −75.68% | −55.79% | −192.89% | −467.46% | −489.22% | −812.88% | −2,870.37% | −10,604.89% | 339.26% | −168.40% | — | — | — | — | — | — |
| Net income | −$13.6M | −$15.8M | −$17.1M | −$108.8M | −$58.3M | −$13.6M | −$27.1M | −$10.2M | −$22.5M | −$28.2M | −$7.7M | −$5.6M | −$57,318 | −$59,675 | −$136,802 | −$60,270 | −$58,894 | −$57,173 | −$48,954 | −$70,441 |
| Net profit margin | −20.43% | −24.31% | −15.88% | −112.53% | −88.81% | −49.29% | −370.65% | −278.36% | −698.67% | −1,099.73% | −2,950.32% | −9,466.80% | −3,275.31% | −3,410.00% | — | — | — | — | — | — |
| Basic EPSper basic share | -$2.16 | -$2.86 | -$5.11 | -$74.01 | -$69.60 | -$60.20 | -$696.00 | -$3,062.00 | -$9,660.00 | -$1,294,800.00 | -$805,600.00 | -$768,000.00 | -$788.57 | -$788.57 | -$2,365.70 | — | — | — | — | — |
| Diluted EPSper diluted share | -$2.16 | -$2.86 | -$5.11 | -$74.01 | -$69.60 | -$60.20 | -$696.00 | -$3,062.00 | -$9,660.00 | -$1,294,800.00 | -$805,600.00 | -$768,000.00 | -$788.57 | -$788.57 | -$2,365.70 | — | — | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Nantahala Capital Management, LLC | 2.17M |
Stonepine Capital Management, LLC | 912.92K |
AWM Investment Company, Inc. | 619.57K |
VANGUARD CAPITAL MANAGEMENT LLC | 261.15K |
Disbrow Joshua R. | 207.2K |
CROWN ADVISORS MANAGEMENT, INC. | 200K |
DIADEMA PARTNERS LP | 148.55K |
TWO SIGMA INVESTMENTS, LP | 105.33K |
RENAISSANCE TECHNOLOGIES LLC | 104.82K |
GEODE CAPITAL MANAGEMENT, LLC | 93.65K |
Disbrow Jarrett | 61.57K |
Selhorn Ryan J | 49.74K |
CITADEL ADVISORS LLC | 49.41K |
VANGUARD FIDUCIARY TRUST CO | 47.05K |
DIMENSIONAL FUND ADVISORS LP | 45.33K |
Persistent Asset Partners Ltd | 37.98K |
PYSZCZYMUKA GREG | 36.1K |
NORTHERN TRUST CORP | 27.93K |
BELLEVUE ASSET MANAGEMENT, LLC | 25.01K |
BlackRock, Inc. | 22.79K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 9, 2025Form 4 | Disbrow JarrettChief Business Officer | BuyCommon Stock | 16.7K | $1.50 | $25.0K | 29.5K |
| Jun 9, 2025Form 4 | Disbrow Joshua R.Chief Executive Officer | BuyCommon Stock | 66.7K | $1.50 | $100.0K | 153.3K |
| Jun 6, 2025Form 4 | Mack Daniel +2TenPercentOwner | BuyPrefunded Warrants · derivative · indirect | 4.00M | $1.50 | $6.00M | 4.82M |
| Feb 28, 2025Form 4 | Disbrow Joshua R.Chief Executive Officer | BuyCommon Stock | 15.0K | $1.30 | $19.5K | 86.6K |
| Dec 30, 2020Form 5 | DOCKERY CARLDirector | SellCommon Shares · indirect | 209 | $6.01 | $1.3K | 0 |